
Celltrion secures EU approval for second Stelara biosimilar Qoyvolma
Celltrion said it has received marketing authorization from the European Commission (EC) for Qoyvolma, its second biosimilar referencing Stelara (ingredient: ustekinumab), a widely used treatment for autoimmune diseases. Stelara, developed by Johnson and …